AbClon said partner Henlius expanded clinical programs for HER2 antibody AC101 to nine, adding a Phase 2 colorectal cancer ...

XYone Therapeutics, Inc. ("XYone"), a clinical-stage biotechnology company, announced that the first patient has been dosed in the first-in-human Phase 1b/2 clinical trial of XYA02(also known as ...

AstraZeneca ( AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics ( SMMT) while launching a clinical collaboration aimed at advancing new cancer treatment ...

Summit Therapeutics (SMMT) shares rose early Tuesday after British drugmaker AstraZeneca (AZN) agreed to invest $2 billion in ...

Shares of Summit Therapeutics Inc. (NASDAQ: SMMT) surged about 20% premarket on Tuesday after AstraZeneca Plc (NYSE: AZN) ...

AstraZeneca agreed to invest $2 billion in Summit Therapeutics, handing its seal of approval to a bispecific cancer drug ...

The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but ...

Generic medicines remain outside the Section 232 pharmaceutical tariff regime, while the latest US Commerce Department notice also creates zero-duty treatment for covered drugs used solely in clinical ...

AstraZeneca (AZN) has made a strategic equity investment of $2 billion in anti-cancer drug developer Summit Therapeutics ...

Alongside India, the participating regions benefiting from the exemption comprise Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, ...

Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in ​the company and collaborate ...